Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PSMA

PSMA

Brief Information

Name:Glutamate carboxypeptidase II
Target Synonym:EC:3.4.17.21,GIG27,Glutamate carboxypeptidase II,NAALADase I,FOLH,Cell growth-inhibiting gene 27 protein,PSM,N-acetylated-alpha-linked acidic dipeptidase I,GCPII,Folylpoly-gamma-glutamate carboxypeptidase,Folate hydrolase 1,FOLH1,Pteroylpoly-Gamma-Glutamate Carboxypeptidase,Membrane Glutamate Carboxypeptidase,Glutamate Carboxypeptidase 2,Glutamate Carboxylase II,NAALAD1,FGCP,PSMA,MGCP,Folate Hydrolase (Prostate-Specific Membrane Antigen) 1,N-Acetylated Alpha-Linked Acidic Dipeptidase 1,Prostate
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:25
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

PSA-HP2Q3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-PSMA CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human PSMA, His Tag (Cat. No. PSA-HP2Q3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

PSA-H5264-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis of Human PSMA, Fc Tag binding to PSMA-CAR-293 cells transfected with anti-PSMA-scFv 2X105 of PSMA-CAR-293 cells transfected with anti-PSMA-scFv were stained with 100μl of 1μg/mL of Human PSMA, Fc Tag (Cat. No. PSA-H5264) and negative control protein respectively, washed and then followed by PE anti-human IgG Fc antibody and analyzed with FACS (Routinely tested).

PSA-H5264-ELISA
Human PSMA, Fc TagHuman PSMA, Fc Tag (Cat. No. PSA-H5264) ELISA bioactivity

Immobilized Human PSMA, Fc Tag (Cat. No. PSA-H5264) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human PSMA Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

PSA-R5245-MALS-HPLC
Rat PSMA, His Tag (Cat. No. ) MALS images

The purity of Rat PSMA, His Tag (Cat. No. PSA-R5245) is more than 90% and the molecular weight of this protein is around 170-208 kDa verified by SEC-MALS.

Bioactivity

Measured by its ability to hydrolyze the substrate N-acetyl-L-Asp-L-Glu into N-acetyl-L-Asp and L-Glu. The L-Glu product is measured by fluorescence after its derivatization by ortho-phthaldialdehyde. The specific activity is >300 pmol/min/μg, as measured under the described conditions (QC tested).

Customer Reviews

Synonym Name

FOLH1,PSMA,GIG27,FOLH,NAALAD1,PSM,NAALADase I,GCPII,FGCP

Background

The biotinylated PSMA protein was conjugated to streptavidin magnetic beads. This pre-coupled magnetic bead product can capture the anti-PSMA antibody from various assay systems. The beads are in uniform size, narrow size distribution with large surface area and unique surface coating, which can help you get the best performance and highly reproducible results. This PSMA coupled magnetic beads will bring great convenience with minimum non-specific binding and developed protocols. This ready-to-use product could greatly save your time and hassle.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Capromab pendetide lndium-CYT-356; Indium-111-CYT-356; CYT-356; 111In CYT-356 Approved Eusa Pharma ProstaScint United States Prostatic Neoplasms Cytogen 1996-10-28 Prostatic Neoplasms Details
Piflufolastat F 18 Approved Johns Hopkins University Pylarify United States Prostatic Neoplasms Progenics Pharmaceuticals Inc 2021-05-26 Carcinoma, Renal Cell; Prostatic Neoplasms Details
Ga-68 PSMA-11 Ga-68-PSMA-11; Ga-68-PSMA; 68Ga-HBED-CC-PSMA11 Approved Radiomedix Gallium Ga 68 Psma-11, ILLUCCIX, Illuccix United States Prostatic Neoplasms Telix Pharmaceuticals Ltd, University Of California, San Francisco Foundation 2020-12-01 Neoplasm Recurrence, Local; Solid tumours; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Carcinoma, Hepatocellular Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
P28z-CAR P28z-CAR Phase 1 Clinical Memorial Sloan Kettering Cancer Center, United States Department Of Defense Prostatic Neoplasms Details
ATL-101 (ATLAB) J-591; MLN-591; huJ-591; muJ-591; 90Y-J591; MLN-591RL; 177Lu-J591; Lu-177-J591 Phase 2 Clinical Cornell University Prostatic Neoplasms Details
INO-5150 INO-5150 Phase 1 Clinical Inovio Prostatic Neoplasms Details
4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute) Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Neoplasms Details
PSMA-CART cell therapy (Shanghai Bioray Laboratory) Phase 1 Clinical Bioray Laboraytories Inc Prostatic Neoplasms Details
HPN-424 HPN-424 Phase 2 Clinical Harpoon Therapeutics Prostatic Neoplasms Details
Gallium-68 PSMA-617 PSMA-617-[68Ga]; 225 Ac-PSMA-617; 68Ga-PSMA-617; 68Ga-DKFZ-617; 68Ga-DOTA-PSMA-DKFZ -617; Gallium-68-PSMA-617; 68Ga-DKFZ-PSMA -617 Clinical Deutsches Krebsforschungszentrum, University Of Heidelberg Prostatic Neoplasms Details
67Cu-SAR-bisPSMA (Clarity Pharmaceuticals) Phase 2 Clinical Prostatic Neoplasms, Castration-Resistant Details
64Cu-SAR-bisPSMA (Clarity Pharmaceuticals) Phase 2 Clinical Prostatic Neoplasms, Castration-Resistant Details
ARX-517 ARX-517 Phase 1 Clinical Ambrx Inc Solid tumours; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
INO-5401 INO5401; INO-5401 Phase 2 Clinical Inovio Glioblastoma; Carcinoma, Transitional Cell Details
89Zr-DFO-huJ591 Zr89-J591; 89Zr-DFO-J591; 89Zr-DFO-huJ591 Phase 2 Clinical Memorial Sloan Kettering Cancer Center Prostatic Neoplasms Details
Anti-PSMA CAR T-cell therapy (TNK Therapeutics) Phase 1 Clinical Sorrento Therapeutics Neoplasms Details
PNT-2002(Point Biopharma) PNT-2002 Phase 3 Clinical Point Biopharma Inc Prostatic Neoplasms Details
CART-PSMA-TGFbRDN (University of Pennsylvania) Phase 1 Clinical University Of Pennsylvania Prostatic Neoplasms Details
[131I]MIP-1095 1095; [131I]MIP-1095; [131I]MIP-1466 Phase 2 Clinical Progenics Pharmaceuticals Inc Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
CBP-1018 CBP-1018 Phase 1 Clinical Coherent Biopharma Suzhou Co Ltd Solid tumours; Carcinoma, Renal Cell; Prostatic Neoplasms; Lung Neoplasms Details
Pelgifatamab BAY-2315497 Phase 1 Clinical Bayer Ag Prostatic Neoplasms Details
CC-1 CC-1 Phase 1 Clinical The University Of Tubingen, Deutsches Krebsforschungszentrum, Dkfz Prostatic Neoplasms Details
Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center Phase 1 Clinical Roger Williams Medical Center Prostatic Neoplasms Details
Acapatamab AMG-160 Phase 2 Clinical Amgen Inc Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
CCW-702 CCW-702 Phase 1 Clinical The Scripps Research Institute, Abbvie Inc Prostatic Neoplasms Details
REGN-4336 REGN-4336 Phase 2 Clinical Regeneron Pharmaceuticals Inc Prostatic Neoplasms Details
Df-IA2BM-Zr-89 IAB2M; 89Zr-Df-IAB2M; Df-IA2BM-Zr-89; 64Cu-NODAGA-PSMA-Mb Phase 2 Clinical Imaginab Inc Prostatic Neoplasms; Glioma Details
TNB-585 AMG-340; TNB-585 Phase 1 Clinical Teneobio, Amgen Inc Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
68Ga-PSMA-R2 (Advanced Accelerator Applications SA) Clinical Advanced Accelerator Applications Sa Prostatic Neoplasms Details
177Lu-PSMA-R2 177Lu-PSMA-SR6; AAA-602; 177Lu-PSMA-R2 Phase 1 Clinical Advanced Accelerator Applications Sa Prostatic Neoplasms Details
LAVA-1207 LAVA-1207 Phase 2 Clinical Vu University Medical Center Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
REGN-5678 REGN-5678 Phase 2 Clinical Regeneron Pharmaceuticals Inc Prostatic Neoplasms Details
Fluorine-18-CTT-1057 CTT-1057; 18F-CTT1057; CTT-1057-18F; CTT-1057-F-18 Phase 3 Clinical Washington University, Cancer Targeted Technology Carcinoma, Renal Cell; Prostatic Neoplasms Details
177Lu-DOTA-rosopatamb TLX591; 177Lu-DOTA-TLX591-CHO Phase 3 Clinical Telix Pharmaceuticals Ltd Prostatic Neoplasms Details
TLX-592 TLX-592 Phase 2 Clinical Telix Pharmaceuticals Ltd Prostatic Neoplasms Details
68Ga-PSMA-IRDye TLX591-Sx Phase 2 Clinical Telix Pharmaceuticals Prostatic Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message